7803 related articles for article (PubMed ID: 2507452)
1. Effect of IFN-gamma treatment and in vivo passage of murine tumor cell lines on their sensitivity to lymphokine-activated killer (LAK) cell lysis in vitro; association with H-2 expression on the target cells.
Tsai L; Ohlén C; Ljunggren HG; Kärre K; Hansson M; Kiessling R
Int J Cancer; 1989 Oct; 44(4):669-74. PubMed ID: 2507452
[TBL] [Abstract][Full Text] [Related]
2. MHC class I up-regulation protects some but not all targets against LAK-mediated lysis: possible implications for the existence of LAK cell subpopulations using different recognition strategies.
Sarin A; Haridas V; Saxena RK
Immunol Lett; 1993 Sep; 38(1):59-62. PubMed ID: 8300155
[TBL] [Abstract][Full Text] [Related]
3. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
4. Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants.
Ljunggren HG; Sturmhöfel K; Wolpert E; Hämmerling GJ; Kärre K
J Immunol; 1990 Jul; 145(1):380-6. PubMed ID: 2113557
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
de Fries RU; Golub SH
J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
[TBL] [Abstract][Full Text] [Related]
6. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
Gorelik E; Gunji Y; Herberman RB
J Immunol; 1988 Mar; 140(6):2096-102. PubMed ID: 3126240
[TBL] [Abstract][Full Text] [Related]
7. Effects of dimethyl sulfoxide treatment on H-2 expression and susceptibility to NK- or cytotoxic T-lymphocyte-mediated lysis of the YAC-1 lymphoma and its beta 2-microglobulin-deficient variant.
Yamasaki T; Klein G; Ljunggren HG; Höglund P; Ohlén C; Petersson MG; Kärre K
J Natl Cancer Inst; 1988 Apr; 80(4):263-9. PubMed ID: 3127594
[TBL] [Abstract][Full Text] [Related]
8. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells.
Naganuma H; Kiessling R; Patarroyo M; Hansson M; Handgretinger R; Grönberg A
Int J Cancer; 1991 Feb; 47(4):527-32. PubMed ID: 1671670
[TBL] [Abstract][Full Text] [Related]
9. Role of major histocompatibility complex class I antigens in modulating the performance of murine tumour cells in cold target competition assays.
Haridas V; Saxena RK
Immunology; 1995 Jan; 84(1):86-90. PubMed ID: 7890307
[TBL] [Abstract][Full Text] [Related]
10. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
Kim TS; Xu WS; Sun T; Cohen EP
Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
[TBL] [Abstract][Full Text] [Related]
11. The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis.
Chang CS; Brossay L; Kronenberg M; Kane KP
J Exp Med; 1999 Feb; 189(3):483-91. PubMed ID: 9927510
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma induces a decrease in the susceptibility of human glioma cells to lysis by lymphokine-activated killer cells.
Yin D; Kondo S; Takeuchi J; Morimura T; Nakatsu S; Oda Y; Kikuchi H
Neurosurgery; 1994 Jul; 35(1):113-8. PubMed ID: 7936131
[TBL] [Abstract][Full Text] [Related]
13. The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis.
Lefor AT; Rosenberg SA
J Surg Res; 1991 Jan; 50(1):15-23. PubMed ID: 1987427
[TBL] [Abstract][Full Text] [Related]
14. Indirect inhibition of generation of murine lymphokine-activated killer cell activity in splenocyte cultures by interferon-gamma.
Chao TY; Ohnishi H; Chu TM
Immunology; 1990 May; 70(1):116-20. PubMed ID: 2113034
[TBL] [Abstract][Full Text] [Related]
15. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1.
Triozzi PL; Eicher DM; Smoot J; Rinehart JJ
Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453
[TBL] [Abstract][Full Text] [Related]
16. Target cell membrane modification and susceptibility to lymphokine activated killer cell mediated lysis. I. Trinitrophenyl has no effect on murine normal cells and tumors.
Lefor AT
J Surg Res; 1991 Oct; 51(4):316-23. PubMed ID: 1921371
[TBL] [Abstract][Full Text] [Related]
17. Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu-overexpressing cells.
Fady C; Gardner AM; Gera JF; Lichtenstein A
Cancer Res; 1992 Feb; 52(4):764-9. PubMed ID: 1346583
[TBL] [Abstract][Full Text] [Related]
18. Effect of interferon gamma on the sensitivity of bovine-papilloma-virus(BPV1)-transformed cell lines to cell-mediated cytotoxicity.
Laatikainen A; Schultz-Suhonen L; Mäntyjärvi R
Cancer Immunol Immunother; 1992; 35(3):205-10. PubMed ID: 1322243
[TBL] [Abstract][Full Text] [Related]
19. Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms.
Bean P; Mazumder A
Immunobiology; 1992 Jun; 185(1):63-77. PubMed ID: 1398742
[TBL] [Abstract][Full Text] [Related]
20. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.
Puri RK; Leland P
Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
